

**Supplementary Table SI.** Demographic and clinical characteristic of patients with CD and UC

| Parameters   | CD (n = 54)                        | UC (n = 82)                                   |
|--|------------------------------------|---|
| Age years, (median, range)   | 14 (6-16)                          | 14 (4-16)                                     |
| Male (n, %)  | 32 (59.26%)                        | 36 (43.90%)                                   |
| Disease activity index (median, range)                             | PCDAI: 27.5 (10-65)                | PUCAI: 40 (10-75)                             |
| IBD activity:  |                                    |   |
| Remission (n, %)   | NA                                 | NA  |
| Mild (n, %)  | 29 (53.70%)                        | 29 (35.37%)                                   |
| Moderate (n, %)  | 8 (14.81%)                         | 37 (45.12%)                                   |
| Severe (n, %)  | 17 (31.48%)                        | 16 (19.51%)                                   |
| Location – L1/L2/L3 (n, %)   | 28 (51.85%)/9 (16.67%)/17 (31.48%) | NA  |
| Behavior – B1/B2 (n, %)  | 29 (53.70%)/25 (46.30%)            | NA  |
| Growth – G1/G0 (n, %)  | 13 (24.07%)/41 (75.93%)            | NA  |
| Extent – E1/E2/E3/E4 (n, %)  | NA                                 | 21 (25.61%)/26 (31.71%)/8 (9.76%)/27 (32.93%) |
| SES-CD (median, range)   | 11 (1-31)                          | NA  |
| Mayo endoscopic score I/II/III (n, %)                              | NA                                 | 15 (18.29%)/34 (41.46%)/33 (40.24%)           |
| Total Mayo score (median, range)                                   | NA                                 | 8 (4-11)                                      |
| Anti-TNF $\alpha$ (n, %)   | 26 (48.15%)                        | 26 (31.71%)                                   |
| IFX/ADA (n, %)   | 20 (76.92%)/6 (23.08%)             | 26 (100.00%)/0 (0.00%)                        |
| Time from diagnosis to anti-TNF treatment (months) (median, range) | 6 (2-23)                           | 8 (2-23)                                      |

UC – ulcerative colitis, CD – Crohn’s disease, PUCAI – pediatric ulcerative colitis activity index, PCDAI – pediatric Crohn’s disease activity index, NA – not applicable, L1 – distal 1/3 ileum, L2 – colonic, L3 – ileocolonic, B1 – non-stricturing, non-penetrating, B2 – stricturing, G0 – no evidence of growth delay, G1 – growth delay, E1 – ulcerative proctitis, E2 – left – sided colitis, E3 – extensive colitis (hepatic flexure distally) , E4 – pancolitis, SES-CD – simple endoscopic score for Crohn’s disease, anti-TNF- $\alpha$  – antibody against tumor necrosis factor  $\alpha$ , IFX – infliximab, ADA – adalimumab.

**Supplementary Table SII.** Trends of parameters at diagnosis and after 8-12 weeks of follow-up in children with CD based on a paired Wilcoxon rank sum test. Median values and ranges are listed in Table I

| Parameter         | T0 vs T1 in Group I |      | T0 vs T1 in Group II |      |
|-------------------|---------------------|------|----------------------|------|
|                   | P                   | R    | P                    | R    |
| ESR               | < 0.001             | 0.82 | 0.002                | 0.62 |
| CRP               | < 0.001             | 0.82 | < 0.001              | 0.72 |
| WBC               | 0.15                | 0.28 | 0.34                 | 0.19 |
| Neutrophil count  | 0.04                | 0.39 | 0.07                 | 0.35 |
| PLT               | 0.44                | 0.15 | 0.003                | 0.59 |
| Hb                | 0.006               | 0.52 | < 0.001              | 0.82 |
| MCV               | 0.44                | 0.15 | < 0.001              | 0.67 |
| Albumin           | < 0.001             | 0.74 | 0.001                | 0.63 |
| PLT/albumin ratio | 0.02                | 0.46 | 0.003                | 0.58 |
| fCal              | 0.02                | 0.44 | 0.11                 | 0.32 |
| PCDAI             | < 0.001             | 0.75 | < 0.001              | 0.72 |

R – effect size, BMI – body mass index, ESR – erythrocyte sedimentation rate, CRP – C-reactive protein, WBC – white blood count, PLT – platelet count, Hb – hemoglobin, MCV – mean corpuscular volume, fCal – fecal calprotectin, PCDAI – Pediatric Crohn’s Disease Activity Index, T0 – at diagnosis , T1 – 8–12 weeks after diagnosis (T1).

**Supplementary Table SIII.** Trends of parameters at diagnosis (T0) and after 8-12 weeks (T1) of follow-up in children with UC. Median values and ranges are listed in Table IV

| Parameter         | T0 vs T1 in Group I |       | T0 vs T1 in Group II |       |
|-------------------|---------------------|-------|----------------------|-------|
|                   | <i>p</i>            | R     | <i>p</i>             | R     |
| ESR               | < 0.001             | 0.629 | 0.02                 | 0.466 |
| CRP               | < 0.001             | 0.521 | 0.17                 | 0.272 |
| WBC               | < 0.001             | 0.502 | 0.19                 | 0.257 |
| Neutrophil count  | < 0.001             | 0.542 | 0.50                 | 0.132 |
| PLT               | < 0.001             | 0.729 | 0.04                 | 0.398 |
| Hb                | < 0.001             | 0.497 | 0.91                 | 0.022 |
| MCV               | 0.14                | 0.197 | 0.48                 | 0.139 |
| Albumin           | < 0.001             | 0.540 | 0.91                 | 0.022 |
| PLT/albumin ratio | < 0.001             | 0.741 | 0.03                 | 0.421 |
| fCal              | < 0.001             | 0.665 | 0.07                 | 0.356 |
| PUCAI             | < 0.001             | 0.843 | 0.003                | 0.583 |

R – effect size, BMI – body mass index, ESR – erythrocyte sedimentation rate, CRP – C-reactive protein, WBC – white blood count, PLT – platelet count, Hb – hemoglobin, MCV – mean corpuscular volume, fCal – fecal calprotectin, PUCAI – Pediatric Ulcerative Colitis Activity Index, T0 – at diagnosis, T1 – 8–12 weeks after diagnosis.